Curcumin in colorectal cancer: mechanistic insights, pharmacological limitations, and translational perspectives
Frontiers in Pharmacology · 29.09.2025 · 16
DOI: 10.3389/fphar.2025.1667731 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.09.2025. Verfasst von Si-Qi Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Curcumin, a natural polyphenolic compound from Curcuma longa , has been extensively investigated for its potential role in colorectal cancer (CRC) prevention and therapy. Preclinical studies suggest that curcumin can modulate gut microbiota composition, influence immune cell subsets such as M1/M2 macrophages, Treg/Th17 cells, and CD8 + T cells, and interfere with oncogenic signaling cascades including NF-κB, PI3K/Akt, and Wnt/β-catenin. These findings collectively highlight curcumin as a biologically active compound with broad mechanistic relevance. However, most evidence derives from in vitro assays at supra-physiological concentrations or high-dose animal models, raising concerns about pharmacological validity and clinical translatability. Curcumin is also recognized as a pan-assay interfering compound (PAINS), which may account for part of its pleiotropic activity and complicates interpretation of preclinical findings. Clinical trials to date have largely confirmed safety and biomarker modulation but have not demonstrated clear improvements in progression-free or overall survival. In this review, we critically appraise the available preclinical and clinical evidence on curcumin in CRC, highlighting both its mechanistic promise and the substantial limitations that constrain its therapeutic relevance, while outlining priorities for future research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China.
- Department of Development and Regeneration, Stem Cell Institute, Katholieke Universiteit (KU) Leuven, Leuven, Belgium.
- Department of Gastrointestinal Surgery, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China.
Zitieren
APA
Li, S. Q., Zhu, X. R., Qin, B. C., & Chen, M. B. (2025). Curcumin in colorectal cancer: mechanistic insights, pharmacological limitations, and translational perspectives. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1667731
Vancouver
Li SQ, Zhu XR, Qin BC, Chen MB. Curcumin in colorectal cancer: mechanistic insights, pharmacological limitations, and translational perspectives. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1667731
BibTeX
@article{Li2025,
author = {Li, Si-Qi and Zhu, Xiao-Ren and Qin, Bai-Chun and Chen, Min-Bin},
title = {Curcumin in colorectal cancer: mechanistic insights, pharmacological limitations, and translational perspectives},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1667731}
}
EUVIMED